Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Muscles In With Post-Brexit Trade Deal Wish List

Executive Summary

US industry lobby group PhRMA wants a future post-Brexit US-UK trade deal to lengthen regulatory data protection for biologicals and to introduce stronger patent protections in the UK. The generics and biosimilars industry has rejected PhRMA's proposals, saying they would delay the launch of competing products in the UK and have a knock-on effect on biologic drug pricing in the US.

You may also be interested in...



US Industry Hauls Post-Brexit UK Over The Coals

PhRMA wants the UK to be placed on the US Trade Representative’s “Watch List” over issues such as the supplementary protection certificate waiver and delays in access to new drugs caused by “overlapping” cost-containment measures.

UK Drug Pricing & IP Targeted As US Gears Up For Post-Brexit Trade Deal Talks

The US has published its final negotiating objectives for a post-Brexit trade deal with the UK, which include pushing for stronger IP protections and changes to UK processes for patient access to new drugs.

UK's NICE Rejects US Industry Attack On Its HTA Methods

The National Institute for Health and Care Excellence does not agree with assertions by the US pharmaceutical industry that its HTA process are “rigid” and “fail to recognize the full value of innovative medicines.”

Related Content

Topics

UsernamePublicRestriction

Register

PS124679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel